Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Interest & Investment Income (2016 - 2025)

Fate Therapeutics' Interest & Investment Income history spans 13 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 42.69% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $11.1 million, down 36.07%, while the annual FY2025 figure was $11.1 million, 36.07% down from the prior year.
  • Interest & Investment Income reached $2.2 million in Q4 2025 per FATE's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.8 million in Q2 2024 to a low of $289000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $2.6 million, with a median of $2.9 million recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: crashed 61.21% in 2021, then surged 869.7% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $297000.0 in 2021, then soared by 869.7% to $2.9 million in 2022, then skyrocketed by 53.26% to $4.4 million in 2023, then dropped by 12.23% to $3.9 million in 2024, then plummeted by 42.69% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Interest & Investment Income are $2.2 million (Q4 2025), $2.6 million (Q3 2025), and $2.9 million (Q2 2025).